NCT06556862 2025-08-13
Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor
Beijing 302 Hospital
Phase 2 Not yet recruiting
Clinical Trials
4 trialsNCT06711094 2024-12-02
Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC
Fujian Medical University
Phase NA Not yet recruiting
NCT05983107 2023-08-09
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05586841 2022-10-19
Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study
Beijing 302 Hospital
Phase 1 Unknown